Acalabrutinib for mantle cell lymphoma

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

“…6 Elderly patients are treated with full or attenuated dose CIT, and rituximab maintenance is commonly delivered across all age groups. 7 At relapse, targeting BTK with ibrutinib, acalabrutinib, or zanubrutinib [8][9][10] is representing the most widely applicable and efficacious approach. Following BTKi failure, the use of novel therapeutic agents such as venetoclax, 11 the re-use of CIT, or chimeric antigen receptor T-cell therapy 12 are therapeutic options.…”

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy

“…Data on acalabrutinib and zanubrutinib seem to go in the same direction as ibrutinib efficacy data, but a more extensive follow-up is needed to confirm such results [50,51].…”

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

“…Acalabrutinib is an FDA approved orally available, covalent, irreversible BTK inhibitor (BTKi) in the treatment of relapsed patients with mantle cell lymphoma (MCL). 1 Although head to head comparison of acalabrutinib vs ibrutinib in MCL is not reported, acalabrutinib appears to have lower incidence of side effects compared to ibrutinib due to its minimal off-target (SRC, EGFR and TEC) kinase inhibitory activity. 2 Furthermore, in the 26 months follow up of ACE-LY-004 study, 3 with acalabrutinib in relapsed MCL patients, the overall response (ORR) and complete response (CR) rate were 81% and 43% respectively and 51% patients discontinued acalabrutinib.…”